Partnerships are an essential element of ImmunGene’s strategy to fully harness the commercial potential of its pipeline and proprietary technology platforms to develop effective therapies. ImmunGene is an ideal partner for pharmaceutical and biotechnology companies who are interested in next generation monoclonal antibody-based therapeutics that provide safe and effective treatments for a wide variety of diseases.
ImmunGene believes that collaborations are vital for both short-term and long-term value creation. We are actively looking for alliances with leading biotechnology and pharmaceutical companies by leveraging our robust platform technology as a tool to expand our capabilities to deliver breakthrough therapeutics to improve people's lives.
ImmunGene, Inc. and Caliber Biotherapeutics, LLC together formed Valor Biotherapeutics, LLC, a joint venture focused on the clinical development and commercialization of monoclonal antibody-interferon (mAb-IFN) fusion protein therapeutics targeting certain cancers. Valor will combine the assets and resources of Caliber with ImmunGene's technologies, know-how, and intellectual property (IP). ImmunGene has granted Valor exclusive licenses to its IP for three mAb-IFN fusion product candidates currently in various stages of preclinical development for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. Caliber will commit sufficient funds to enable Valor to reach certain development milestones including the human proof-of-concept for two programs plus IND ready status for the third one.
We strive to work on collaborations that will provide us the opportunity to enhance our internal research and programs through exchange of technology and therapeutic programs. ImmunGene is also open to license its technology and developmental programs.
Companies interested in exploring partnering opportunities with ImmunGene or learning about our technology should contact: bd@immunGene.com